| 0 |
LYMPHATIC OBSTRUCTION |
1 |
0.0116 |
| 1 |
APPLICATION SITE NODULE |
1 |
0.0073 |
| 2 |
ANAL INFECTION |
1 |
0.0039 |
| 3 |
INJECTION SITE CYST |
1 |
0.0034 |
| 4 |
VULVITIS |
1 |
0.0030 |
| 5 |
SKIN LAXITY |
1 |
0.0023 |
| 6 |
POSITRON EMISSION TOMOGRAM ABNORMAL |
1 |
0.0014 |
| 7 |
BILIARY DILATATION |
1 |
0.0007 |
| 8 |
LEUKAEMIA RECURRENT |
1 |
0.0006 |
| 9 |
INTRA-ABDOMINAL FLUID COLLECTION |
1 |
0.0006 |
| 10 |
APPLICATION SITE DISCOMFORT |
1 |
0.0006 |
| 11 |
BLOOD IRON INCREASED |
1 |
0.0005 |
| 12 |
HYPOREFLEXIA |
1 |
0.0005 |
| 13 |
PNEUMONIA CYTOMEGALOVIRAL |
1 |
0.0005 |
| 14 |
APPLICATION SITE HAEMORRHAGE |
1 |
0.0004 |
| 15 |
BONE MARROW DISORDER |
1 |
0.0003 |
| 16 |
VENOUS THROMBOSIS |
1 |
0.0003 |
| 17 |
CYTOMEGALOVIRUS INFECTION REACTIVATION |
1 |
0.0002 |
| 18 |
GASTROINTESTINAL INFECTION |
2 |
0.0002 |
| 19 |
MALABSORPTION |
1 |
0.0002 |
| 20 |
PROSTATIC SPECIFIC ANTIGEN INCREASED |
2 |
0.0001 |
| 21 |
PRODUCT SUPPLY ISSUE |
1 |
0.0001 |
| 22 |
GASTROINTESTINAL INFLAMMATION |
1 |
0.0001 |
| 23 |
BLOOD MAGNESIUM DECREASED |
1 |
0.0001 |
| 24 |
LIGAMENT SPRAIN |
1 |
0.0001 |
| 25 |
INJECTION SITE DISCOMFORT |
1 |
0.0001 |
| 26 |
INJECTION SITE NODULE |
1 |
0.0001 |
| 27 |
TOOTH FRACTURE |
1 |
0.0001 |
| 28 |
MALNUTRITION |
1 |
0.0001 |
| 29 |
CYST |
1 |
0.0001 |
| 30 |
MUSCLE ATROPHY |
1 |
0.0001 |
| 31 |
IMMUNE SYSTEM DISORDER |
1 |
0.0001 |
| 32 |
DEVICE RELATED INFECTION |
1 |
0.0001 |
| 33 |
PNEUMOTHORAX |
1 |
0.0001 |
| 34 |
METASTASES TO LIVER |
1 |
0.0001 |
| 35 |
APPLICATION SITE PAIN |
1 |
0.0000 |
| 36 |
PRESYNCOPE |
1 |
0.0000 |
| 37 |
HEPATITIS |
1 |
0.0000 |
| 38 |
GASTRITIS |
1 |
0.0000 |
| 39 |
LIMB INJURY |
1 |
0.0000 |
| 40 |
ASCITES |
1 |
0.0000 |
| 41 |
BLOOD POTASSIUM DECREASED |
1 |
0.0000 |
| 42 |
HEART RATE DECREASED |
1 |
0.0000 |
| 43 |
DYSURIA |
1 |
0.0000 |
| 44 |
INJECTION SITE MASS |
1 |
0.0000 |
| 45 |
LUNG NEOPLASM MALIGNANT |
1 |
0.0000 |
| 46 |
LUNG DISORDER |
1 |
0.0000 |
| 47 |
FLUID RETENTION |
1 |
0.0000 |
| 48 |
INFLAMMATION |
1 |
0.0000 |
| 49 |
BRADYCARDIA |
1 |
0.0000 |
| 50 |
WHITE BLOOD CELL COUNT DECREASED |
2 |
0.0000 |
| 51 |
HAEMATOCHEZIA |
1 |
0.0000 |
| 52 |
OXYGEN SATURATION DECREASED |
1 |
0.0000 |
| 53 |
BONE PAIN |
1 |
0.0000 |
| 54 |
DISEASE PROGRESSION |
2 |
0.0000 |
| 55 |
PLEURAL EFFUSION |
1 |
0.0000 |
| 56 |
SLEEP DISORDER |
1 |
0.0000 |
| 57 |
THERAPY INTERRUPTED |
1 |
0.0000 |
| 58 |
INJECTION SITE SWELLING |
1 |
0.0000 |
| 59 |
ABDOMINAL DISCOMFORT |
2 |
0.0000 |
| 60 |
SKIN EXFOLIATION |
1 |
0.0000 |
| 61 |
SWELLING |
1 |
0.0000 |
| 62 |
ANAEMIA |
2 |
0.0000 |
| 63 |
MALIGNANT NEOPLASM PROGRESSION |
1 |
0.0000 |
| 64 |
ABDOMINAL DISTENSION |
1 |
0.0000 |
| 65 |
CONSTIPATION |
2 |
0.0000 |
| 66 |
INFLUENZA |
1 |
0.0000 |
| 67 |
THROMBOCYTOPENIA |
1 |
0.0000 |
| 68 |
WEIGHT INCREASED |
2 |
0.0000 |
| 69 |
MUSCULAR WEAKNESS |
1 |
0.0000 |
| 70 |
DECREASED APPETITE |
2 |
0.0000 |
| 71 |
ABDOMINAL PAIN |
2 |
0.0000 |
| 72 |
RENAL FAILURE |
1 |
0.0000 |
| 73 |
DRY SKIN |
1 |
0.0000 |
| 74 |
NEUTROPENIA |
1 |
0.0000 |
| 75 |
PRODUCT DOSE OMISSION ISSUE |
2 |
0.0000 |
| 76 |
MYALGIA |
1 |
0.0000 |
| 77 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
1 |
0.0000 |
| 78 |
NASOPHARYNGITIS |
1 |
0.0000 |
| 79 |
CHEST PAIN |
1 |
0.0000 |
| 80 |
ALOPECIA |
1 |
0.0000 |
| 81 |
ABDOMINAL PAIN UPPER |
1 |
0.0000 |
| 82 |
INSOMNIA |
1 |
0.0000 |
| 83 |
WEIGHT DECREASED |
1 |
0.0000 |
| 84 |
COUGH |
1 |
0.0000 |
| 85 |
OFF LABEL USE |
3 |
0.0000 |
| 86 |
INJECTION SITE PAIN |
1 |
0.0000 |
| 87 |
DIARRHOEA |
2 |
0.0000 |
| 88 |
FALL |
1 |
0.0000 |
| 89 |
PYREXIA |
1 |
0.0000 |
| 90 |
MALAISE |
1 |
0.0000 |
| 91 |
VOMITING |
1 |
0.0000 |
| 92 |
DIZZINESS |
1 |
0.0000 |
| 93 |
PAIN |
1 |
0.0000 |
| 94 |
HEADACHE |
1 |
0.0000 |
| 95 |
NAUSEA |
1 |
0.0000 |
| 96 |
DEATH |
1 |
0.0000 |